Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update
Anavex Life Sciences Announces First Participant Enrolled in Phase 1 Study of ANAVEX®3-71 (AF710B)
Anavex Life Sciences Announces Initiation of First-in-Human Phase 1 Study of ANAVEX®3-71 (AF710B)
Follow us on social media
